Management of opioid addiction with buprenorphine: French history and current management

International Journal of General Medicine

Volumn 7, Issue , 2014, Pages 143-148

  Poloméni, Pierre ^a   Schwan, Raymund ^b,c  

^a Hôpitaux Universitaires Paris Seine Saint Denis   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c General psychiatric Division for the Greater Nancy Urban Community Psychotherapeutic Center of Nancy   (France)

Author keywords

Buprenorphine; General medicine; Naloxone; Opioid addiction; Opioid substitution treatment; Withdrawal

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; METHADONE;

ARTICLE; COMORBIDITY; DISEASE ASSOCIATION; DISTRESS SYNDROME; DRUG MISUSE; FRANCE; GENERAL PRACTITIONER; HEALTH CARE POLICY; HEPATITIS C; HEROIN DEPENDENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PRACTICE GUIDELINE; PRESCRIPTION; PUBLIC HEALTH SERVICE; QUALITY OF LIFE; RESPIRATION DEPRESSION; VIRUS TRANSMISSION; WITHDRAWAL SYNDROME;

EID: 84897875947     PISSN: None     EISSN: 11787074     Source Type: Book Series    
DOI: 10.2147/IJGM.S53170     Document Type: Article

References (31)

1. European Monitoring Centre for Drugs and Drug Addiction. [National report on 2012 (data 2011) at OEDT by the French focal point of the network Reitox, new developments, trends and detailed information about specific topics]. Available from: http://www.ofdt.fr/BDD/publications/ docs/efnxofsc.pdf. Accessed June 25, 2013. French.
2. Observatoire français des drogues et toxicomanies. Drogues, chiffres-clés. 4 édition. [French monitoring center (observatory) of drugs and drug addiction 2012]. Available from: http://www.ofdt.fr/BDD/publications/docs/dcc2012.pdf. Accessed June 25, 2013. French.
3. French federation of addiction (FFA) and Anaes. [Therapeutic strategies for the people dependent on opiates: instead of the substitution treatment]. Presented at: Consensus Conference; June 23-24, 2004; Lyon, France. Available from: http://www.has-sante.fr/portail/upload/docs/application/pdf/TSO_court.pdf. Accessed June 25, 2013. French.
4. Evolution du nombre de décès par surdose depuis 1985 [webpage on the Internet]. Cedex: Observatoire français des drogues et toxicomanies; 2010. Available from: http://www.ofdt.fr/BDD_len/seristat/00003.xhtml. Accessed June 25, 2013. French.
5. World Health Organization Department of Mental Health and Substance Abuse. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence [webpage on the Internet]. Geneva: World Health Organization; 2009. Available from: http://www.who.int/hiv/pub/idu/opioid/en/. Accessed June 25, 2013.
6. Feroni I, Peretti-Watel P, Masut A, Coudert C, Paraponaris A, Obadia Y. French general practitioners' prescribing high-dosage buprenorphine maintenance treatment: is the existing training (good) enough? Addict Behav. 2005;30(1):187-191.
7. Wise RA, Bozarth MA. Action of drugs of abuse on brain reward systems: an update with specific attention to opiates. Pharmacol Biochem Behav. 1982;17(2):239-243.
8. Morency MA, Beninger RJ. Dopaminergic substrates of cocaine-induced place conditioning. Brain Res. 1986;399(1):33-41.
9. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A. 1988;85(14): 5274-5278.
10. Di Chiara G, Bassareo V, Fenu S, et al. Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology. 2004;47 Suppl 1:227-241.
11. Mazei-Robison MS, Koo JW, Friedman AK, et al. Role for mTOR signaling and neuronal activity in morphine-induced adaptations in ventral tegmental area dopamine neurons. Neuron. 2011;72(6): 977-990.
12. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;3:CD002209.
13. McLellan AT, Arndt IO, Metzger DS, Woody GE, O'Brien CP. The effects of psychosocial services in substance abuse treatment. JAMA. 1993;269(15):1953-1959.
14. Miotto K, Hillhouse M, Donovick R, et al. Comparison of buprenor-phine treatment for opioid dependence in 3 settings. J Addict Med. 2012;6(1):68-76.
15. Raisch DW, Campbell HM, Garnand DA, et al. Health-related quality of life changes associated with buprenorphine treatment for opioid dependence. Qual Life Res. 2012;21(7):1177-1183.
16. Dole VP, Nyswander ME, Kreek MJ. Narcotic blockade - a medical technique for stopping heroin use by addicts. Trans Assoc Am Physicians. 1966;79:122-136.
17. Jasinski DR, Haertzen CA, Henningfield JE, Johnson RE, Makhzoumi HM, Miyasato K. Progress report of the NIDA Addiction Research Center. NIDA Res Monogr. 1982;41:45-52.
18. Mello NK, Mendelson JH. Behavioral pharmacology of buprenorphine. Drug Alcohol Depend. 1985;14(3-4):283-303.
19. Lange WR, Fudala PJ, Dax EM, Johnson RE. Safety and side-effects of buprenorphine in the clinical management of heroin addiction. Drug Alcohol Depend. 1990;26(1):19-28.
20. Agence Français de Sécurité Sanitaire des produits de Santé. Initiation et suivi du traitement substitutif de la pharmacodépendance majeure aux opiacés par buprénorphine haut dosage. Mise au point. Oct 2011. Available from: http://ansm.sante.fr/var/ansm_site/storage/original/application/b275587447c30549b123fe6c29f4c76b.pdf. Accessed June 25, 2013.
21. Gowing L, Ali R, White JM. Buprenorphine for the management of opi-oid withdrawal. Cochrane Database Syst Rev. 2009;3: CD002025.
22. Worksheet for DSM-IV criteria for diagnosis of opioid dependence. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, text revision. Washington; American Psychiatric Association; 2000:197.
23. Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003;361(9358):662-668.
24. Haddad MS, Zelenev A, Altice FL. Integrating buprenorphine maintenance therapy into federally qualifed health centers: real-world substance abuse treatment outcomes. Drug Alcohol Depend. 2013;131(1-2): 127-135.
25. Rowe TA, Jacapraro JS, Rastegar DA. Entry into primary care-based buprenorphine treatment is associated with identifcation and treatment of other chronic medical problems. Addict Sci Clin Pract. 2012;7(1):22.
26. Di Nino F, Imbs JL, Melenotte GH, Doffoel M. Dépistage et traitement des hépatites C par le réseau des microstructures médicales chez les usagers de drogues en Alsace, France, 2006-2007. BEH. 2009;37(6): 400-404.
27. Karow A, Verthein U, Pukrop R, et al. Quality of life profles and changes in the course of maintenance treatment among 1,015 patients with severe opioid dependence. Subst Use Misuse. 2011;46(6):705-715.
28. Kornør H, Waal H, Ali RL. Abstinence-orientated buprenorphine replacement therapy for young adults in out-patient counselling. Drug Alcohol Rev. 2006;25(2):123-130.
29. Feelemyer J, Des Jarlais D, Arasteh K, Abdul-Quader AS, Hagan H. Retention of participants in medication-assisted programs in low- and middle-income countries: an international systematic review. Addiction. Epub July 17, 2013.
30. Substance abuse and mental health services administration. Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. A Treatment Improvement Protocol TIP 43; 2005, revised 2012. Rockville, MD: US Department of Health and Human Service. Available from: http://radar.boisestate.edu/pdfs/TIP43%281%29.pdf. Accessed June 25, 2013.
31. Doran C, Holmes J, Ladewig D, Ling W. Buprenorphine induction and stabilisation in the treatment of opiate dependence. Heroin Add Relat Clin Probl. 2005;7(1):7-18.